Novo Nordisk and GE HealthCare Collaborate to Explore Ultrasound-Based Therapy for Type 2 Diabetes and Obesity

Oct 20, 2023 14:25 CST Updated 14:25

GE Healthcare

Digital Solution Provider

Novo Nordisk

Insulin Developer and Manufacturer

Welcome to follow Asymchem Pharma News

On October 19, 2023, GE HealthCare announced a collaboration with Novo Nordisk to further advancePeripheral Focused Ultrasound (PFUS, Peripheral Focused Ultrasound Stimuli)Clinical and product development aims to use ultrasonic new technology to specifically modulate metabolic functions within the body, applying non-invasive bioelectronic medicine to support the treatment of chronic diseases such as type 2 diabetes and obesity.

This collaboration builds on the extensive foundational research conducted by the GE Healthcare team to date,The existing PFUS technology was developed by a group of scientists at GE Healthcare's Technology and Innovation Center, which was formerly part of GE Research.

As part of the collaboration, GE and Novo Nordisk will contribute their respective expertise in ultrasound medical technology and the treatment and management of metabolic diseases. Together, they will develop Peripheral Focused Ultrasound (PFUS) solutions to enhance patient care.

Other terms of the agreement were not disclosed.

About PFUS

Peripheral Focused Ultrasound (PFUS) is a non-invasive bioelectronic medicine that uses ultrasound to activate the nervous system to stimulate responses potentially capable of treating diseases.

Preclinical proof-of-concept and preliminary early clinical studies have shown that it can influence glucose metabolism in patients with diabetes through personalized ultrasound stimulation of neural pathways.

If further clinical evidence validates, PFUS may represent a non-pharmacological approach to normalizing blood glucose levels in patients with type 2 diabetes.

Schematic Diagram of Peripheral Focused Ultrasound Stimulation Technology

The journal NATURE BIOMEDICAL ENGINEERING (IF: 25.671) published a research article on PFUS:

Researchers used PFUS technology to explore stimulation of the liver region, which contains the hepatic portal plexus responsible for transmitting information such as glucose and nutrient status to the brain. However, due to its neural structure being too small for individual stimulation with implanted electrodes, it has been difficult to study.

New research shows,In ChinaTargeted burst action using PFUS in the liver area successfully reversed the onset of hyperglycemia, and it was also found that this treatment was effective in three different animal models of diabetes (Mice, rats, and pigs)Effective in China.

Study finds: In animal models of diabetes, using PFUS technology to stimulate specific sensory nerves in the liver for just 3 minutes a day can restore blood sugar levels to normal. This non-pharmacological approach holds promise for the prevention or reversal of type 2 diabetes.

Novo Nordisk's Recent Collaborative Explorations in the Diabetes Field

In addition to product layout, Novo Nordisk has engaged in various collaborations with many companies in the industry to strengthen its competitiveness and broaden the boundaries of innovation.

· In June 2018, Novo Nordisk entered into a collaboration research and option agreement with Kallyope, a biotechnology company based in New York, to jointly develop novel peptide-based drugs for the treatment of obesity and diabetes.

· In September 2019, Novo Nordisk and Medtronic announced a partnership to integrate their respective digital products into diabetes care, including data sharing between continuous glucose monitoring devices and smart insulin pens.

· In December 2020, Novo Nordisk entered into an exclusive research collaboration and license agreement with Procyon Technologies to develop an implantable cell encapsulation device, which will be used in the development of Novo Nordisk's innovative therapy for type 1 diabetes.

· In September 2022, Novo Nordisk entered into a licensing agreement with Zealand Pharma for the development, regulatory, manufacturing, and commercialization of Zegalogue (dasiglucagon), with a total deal value of $45.75 million. Zegalogue is a glucagon analog approved in March 2021 for the treatment of severe hypoglycemia in pediatric patients aged 6 years and older and adults with diabetes. The addition of this product to Novo Nordisk's portfolio complements its therapeutic options for patients with hypoglycemic diabetes.

· March 22, 2023，Novo Nordisk Partners with Dewpoint Therapeutics to Leverage Dewpoint’s Breakthrough Discoveries and AI Technology Platform for Identifying Modulators of Biomolecular Condensates

· On April 12, 2023, a collaboration was reached with Canadian biotechnology company Aspect Biosystems to introduce four bioprinted tissue therapies for the treatment of diabetes and obesity.

……

Summary:

Personalized peripheral focused ultrasound therapy has the potential to serve as a non-invasive, non-pharmacological alternative for chronic disease management. Encouraging preclinical and early clinical data suggest its potential use for patients with type 2 diabetes. The combination of GE Healthcare's expertise in ultrasound technology and Novo Nordisk's long-standing experience in metabolic disease treatment and management is expected to lead to the development of more solutions to improve patient care.

References

1. Family Care for Diabetes

Thank you for your attention.、Forward,For authorization to reproduce, or to join industry exchange groups, please add the administrator's WeChat ID "hxsjjf1618"。

"Views"Click once